Evidence map›Paper›PMID 34665829›Full record

ArticlePloS one2021

Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment.

Michele P Andrasik, Gail B Broder, Stephaun E Wallace, Richa Chaturvedi, Nelson L Michael, Sally Bock, Chris Beyrer, Linda Oseso, Jasmin Aina, Jonathan Lucas and 3 more

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Improving COVID-19 Vaccine Uptake among Black Populations: A Systematic Review of Strategies.International journal of environmental research and public health · 2022
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Article
  15. Building Trust and Engaging Communities for HIV Prevention Research Globally.AIDS education and prevention : official publication of the International Society for AIDS Education · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Michele P AndrasikVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0003-1952-7825
Gail B BroderVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0002-5352-3097
Stephaun E WallaceVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0003-3578-7440
Richa ChaturvediStatistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Nelson L MichaelWalter Reed Army Institute of Research, Silver Spring, MD, United States of America.
Sally BockFred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Chris BeyrerJohn's Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
Linda OsesoVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.ORCID 0000-0002-6513-0119
Jasmin AinaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
Jonathan LucasHIV Prevention Trials Network, FHI360, Research Triangle, NC, United States of America.
David R WilsonTribal Health Research Office, National Institutes of Health, Bethesda, MD, United States of America.
James G KublinVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States of America.
George A MensahNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States of America.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
NIAID NIH HHS UM1 AI068614NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068635
6 · The paper itself

Abstract

Longstanding social and economic inequities elevate health risks and vulnerabilities for Black, Indigenous and People of Color (BIPOC) communities. Engagement of BIPOC communities in infectious disease research is a critical component in efforts to increase vaccine confidence, acceptability, and uptake of future approved products. Recent data highlight the relative absence of BIPOC communities in vaccine clinical trials. Intentional and effective community engagement methods are needed to improve BIPOC inclusion. We describe the methods utilized for the successful enrollment of BIPOC participants in the U.S. Government (USG)-funded COVID-19 Prevention Network (CoVPN)-sponsored vaccine efficacy trials and analyze the demographic and enrollment data across the efficacy trials to inform future efforts to ensure inclusive participation. Across the four USG-funded COVID-19 vaccine clinical trials for which data are available, 47% of participants enrolled at CoVPN sites in the US were BIPOC. White enrollment outpaced enrollment of BIPOC participants throughout the accrual period, requiring the implementation of strategies to increase diverse and inclusive enrollment. Trials opening later benefitted considerably from strengthened community engagement efforts, and greater and more diverse volunteer registry records. Despite robust fiscal resources and a longstanding collaborative and collective effort, enrollment of White persons outpaced that of BIPOC communities. With appropriate resources, commitment and community engagement expertise, the equitable enrollment of BIPOC individuals can be achieved. To ensure this goal, intentional efforts are needed, including an emphasis on diversity of enrollment in clinical trials, establishment of enrollment goals, ongoing robust community engagement, conducting population-specific trials, and research to inform best practices.

Indexed as

Black or African AmericanIndians, North AmericanMotivationPatient ParticipationSARS-CoV-2VaccinationClinical Trials as TopicCOVID-19COVID-19 VaccinesHumansRisk FactorsUnited StatesCOVID-19 Vaccines

Identifiers

PMID34665829
PMCPMC8525736

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.